Clinical Trial Update: QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy [Phase 1, Phase 2]

View source ↗

Summary

The QUILT-3.049 trial of the NANT TNBC vaccine in triple-negative breast cancer has been withdrawn, ending a Phase 1/2 combination immunotherapy study in patien…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• NANT TNBC Vaccine

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: Triple Negative Breast Cancer | Phase 1, Phase 2 | Status: WITHDRAWN